Pyrazolo[3,4-d]Pyrimidine Combinations for Selective HER2 Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antitumor agents, such as HER2 inhibitors, often cause adverse effects due to non-specific kinase inhibition, and there is a need for a compound that enhances antitumor effects while minimizing toxicity.
Innovation Solution
The use of pyrazolo[3,4-d]pyrimidine compounds in combination with other antitumor agents, such as 5-FU, gemcitabine, and trastuzumab, to synergistically enhance antitumor effects without increasing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HER2 inhibitors are used to treat cancer, then antitumor effect is improved, but adverse effects increase due to non-specific kinase inhibition
Solution Approach 1:
The patent applies local quality by designing the pyrazolo[3,4-d]pyrimidine compound with specific structural features (substituents at positions 1, 4, and 5) that confer selective binding affinity to HER2 kinase while minimizing interaction with other kinase families. This structural differentiation enables the drug to exert its antitumor effect locally at the HER2 target site without broadly inhibiting other kinases, thereby reducing adverse effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical structure parameters of the pyrazolo[3,4-d]pyrimidine core (including different substituent groups R1-R6, R7-R12, and their configurations) to optimize the balance between HER2 binding affinity and selectivity. By adjusting these molecular parameters, the compound achieves enhanced antitumor efficacy against HER2-positive cancers while maintaining a favorable safety profile through reduced off-target kinase inhibition.
2Reliability
If pyrazolo[3,4-d]pyrimidine compounds are used in combination with other antitumor agents, then antitumor effect is enhanced, but treatment complexity increases
Solution Approach 1:
The patent applies merging by combining the pyrazolo[3,4-d]pyrimidine compound with other antitumor agents in a coordinated treatment regimen. The combination therapy merges the mechanisms of action of different drugs (HER2-selective kinase inhibition from the pyrazolo[3,4-d]pyrimidine compound with other antitumor mechanisms) to achieve synergistic or additive antitumor effects, particularly in treating HER2-positive cancers where the compounds demonstrate enhanced efficacy compared to monotherapy.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
To provide a method for treating cancer using a pyrazolo[3,4-d]pyrimidine compound or a salt thereof. The present invention provides an antitumor agent comprising a pyrazolo[3,4-d]pyrimidine compound of formula (I) wherein X, Y, Z1, Z2, Z3, Z4, W, n, R1, R2, and R3 have meanings as defined in the present specification, or a salt thereof and other antitumor agent(s) for combined administration.